Labetalol, a cross-over double blind controlled trial.
20 patients (12 female) with moderately severe essential hypertension [blood pressure during placebo treatment 181 +/- 6 (systolic), 107 +/- 3 (diastolic)] completed a double-blind, cross-over dose-titrated comparison of labetalol and methyldopa. Both drugs reduced lying and standing arterial blood pressure to a similar extent, although only labetalol reduced heart rate. Compliance was high (greater than 95%) with both drugs, and the incidence of subjective adverse effects was similar.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007741:Labetalol / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008750:Methyldopa / Q000009:adverse effects / Q000627:therapeutic use; D010919:Placebos
D004983:Ethanolamines; D010919:Placebos; D008750:Methyldopa; D007741:Labetalol